- About MBT
- First-in-class oncology medicines targeting human kinome.
Leadership
- Taebo Sim, Ph.D.
- Founder / CEO
- Experience & Education
-
- Professor, Yonsei University College of Medicine (2019 ~ Present)
- Professor, KU-KIST Graduate School of Converging Science and Technology, Korea University (2007 ~ 2019)
- Head of Chemical Kinomics Research Center, KIST (2011 ~ 2019)
- Principle investigator, KIST(2007 ~ 2019)
- Senior scientist, Dana-Farber Cancer Institute / Harvard Medical School (2006 ~ 2007)
- Principle investigator / Project leader, The Genomics Institute of the Novatis Research Foundation (2002 ~ 2006)
- Senior/ Principle research scientist, CKD Pharmaceutical (1999 ~ 2001)
- Postdoctoral Fellow, U.C. Berkeley (1997 ~ 1998)
- Significant Research Achievements
-
View more
- Ha-soon Choi, Ph.D.
- Co-founder / CTO. VicePresident
- Experience & Education
-
- Senior principle investigator / Group leader, Novatis
- Senior scientist, DuPont Pharmaceutical
- Postdoctoral Fellow, Scripps Research
- Significant Research Achievements
-
- 25 papers, 11 patents
- 2 Phase II, 2 Phase I, 7 Preclinical
- New drug development using new modality
- TRPC (Transient receptor potential channel)
- Regenerative Medicine
- ADC
-
View more
